SUPPORTING INFORMATION

The mitochondrial amidoxime reducing component (mARC) is involved in detoxification of *N*-hydroxylated base analogues

Nina Krompholz, Carmen Krischkowski, Debora Reichmann, Dieter Garbe-Schönberg, Florian Bittner, Ralf-R. Mendel, Bernd Clement^{*}, Antje Havemeyer

Table of contents	page
SUPPLEMENTARY FIGURE S1:	S2
SUPPLEMENTARY FIGURE S2:	S 3

SUPPLEMENTARY FIGURE S1:

Western blot analysis of subcellular hepatic fractions

 $0.05 \ \mu g$ recombinant protein mARC1/mARC2, $20 \ \mu g$ (A,B,C) or $12 \ \mu g$ (D,E) hepatic fraction per lane was subjected to SDS-PAGE, for immunoblot analysis anti-mARC1 antibody, anti-mARC2 antibody, anti-GAPDH antibody, anti-VDAC antibody or anti-calnexin antibody was used. Masses are indicated in kDa to the left of each panel.



SUPPLEMENTARY FIGURE S2:

Western blot analysis of mARC1 and mARC2 in the porcine hepatic and extrahepatic mitochondria

0.05 µg recombinant protein mARC1/mARC, 20 µg (anti-mARC1 Blot) or 15 µg (anti-mARC2 Blot) mitochondrial fraction per lane was subjected to SDS-PAGE, for immunoblot analysis anti-mARC1 or anti-mARC2 antibody was used. Masses are indicated in kDa to the left of each panel.

